Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Evaluating More Lymph Nodes May Not Improve Identification Of Late-Stage Colorectal Cancer
Surgically removing and evaluating an increasing number of lymph nodes does not appear to identify a greater number of patients with stage III colorectal cancer, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.

Intense, Prolonged Exposure To World Trade Center Attack Associated With New Health Problems Several Years Later
Large number of individuals, such as recovery and rescue workers, nearby residents and office workers, who experienced intense or prolonged exposure to the World Trade Center attack have reported new diagnoses of asthma or posttraumatic stress 5-6 years after the attack, according to a study in the August 5 issue of JAMA, a theme issue on violence and human rights.
News of the day
Washington Post Examines Future Of USAID, Foreign Policy Reports Farmer No Longer Under Consideration For Agency Top Spot
USAID, "the main U.S. foreign aid agency is in limbo, entering its seventh month without a permanent director despite pledges by the Obama administration to expand development assistance and improve its effectiveness in poor countries," the Washington Post reports in an article examining the agency"s prospects and concerns that changes could reduce its clout. "While [Secretary of State Hillary Rodham] Clinton has championed additional personnel for USAID, aid groups worry that the once-autonomous agency could be swallowed up in the State Department, with long-term development goals losing out to short-term political aims," the Washington Post writes. The article includes comments from development experts and administration officials on USAID"s future.
Sexual Health

Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida. The study results further underpin the broad predictive and prognostic power of Agendia"s breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia"s new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions: Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract #512 Time: 5:00PM - 5:15PM Location: Level 2, West Hall D1 The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, L. J. Van "t Veer Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract # LBA515 Time: 3:00PM - 6:00PM Location: Level 2, West Hall D1 Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van "t Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators Date: Saturday, May 30, 2009 POSTER PRESENTATION Abstract #6570 Time: 2:00PM - 6:00PM Location: Level 2, West Hall C Cost effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early stage breast cancer (ESBC) patients K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #535 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guideline F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van "t Veer Date: Sunday, May 31, 2009 POSTER PRESENTATION Abstract #4036 Time: 8:00 AM - 12:00 PM Location: Level 2, West Hall C Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van "t Veer, R. Tollenaar Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #518 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Early determination of metastatic potential in breast cancer: the 70-gene signature in small tumors M. Knauer, S. Mook, V. Retç¨l, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van "t Veer, S. C. Linn Date: Monday, June 01, 2009 POSTER PRESENTATION Abstract #11083 Time: 1:00PM - 5:00PM Location: Level 2, West Hall C Combining multi-gene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas About MammaPrint(R) MammaPrint is the first "in vitro diagnostic multivariate index assay" (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests. All MammaPrint tests are conducted in Agendia"s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process. Agendia B.V.

Breast Implant commented:

I totally agree with the tips mentioned in this article. One can improve the visitors in a best possible way.

19.05.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009